Bleeding Disorder, A Newly Recognized Adverse Event Following Sacubitril/Valsartan Therapy
{{output}}
Introduction: Sacubitril/valsartan (Entresto) is the only currently approved angiotensin receptor-neprilysin inhibitor (ARNI) drug. It demonstrates important therapeutic outcomes in heart failure patients by reducing hospitalizat... ...
